PBAC Recommendation for nirmatrelvir and ritonavir (Paxlovid®) March 2022
Page last updated: 9 April 2022
The Pharmaceutical Benefits Advisory Committee (PBAC) undertook an expedited consideration of a submission to add the combination product, nirmatrelvir and ritonavir (Paxlovid®) to the Pharmaceutical Benefits Scheme (PBS) for use in treating patients with mild to moderate COVID-19 who are at risk of developing severe disease requiring hospitalisation. The expedited consideration by PBAC recognises the urgent public health need related to the prevention, management, or treatment of SARS-CoV-2 infections. The PBAC recommended the listing on the PBS of nirmatrelvir and ritonavir as a General Schedule, Authority Required (STREAMLINED) benefit. The outcome of the PBAC consideration is available on the PBS website.